Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
View ORCID ProfileStéphane Le Vu, View ORCID ProfileMarion Bertrand, View ORCID ProfileMarie-Joëlle Jabagi, View ORCID ProfileJérémie Botton, View ORCID ProfileAlain Weill, View ORCID ProfileRosemary Dray-Spira, View ORCID ProfileMahmoud Zureik
doi: https://doi.org/10.1101/2022.07.31.22278064
Stéphane Le Vu
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marion Bertrand
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marie-Joëlle Jabagi
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Jérémie Botton
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
2Faculté de Pharmacie, Université Paris-Saclay, 92296, Châtenay-Malabry, France
Alain Weill
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Rosemary Dray-Spira
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Mahmoud Zureik
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
3University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, Montigny le Bretonneux, France

Article usage
Posted August 01, 2022.
Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
Stéphane Le Vu, Marion Bertrand, Marie-Joëlle Jabagi, Jérémie Botton, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik
medRxiv 2022.07.31.22278064; doi: https://doi.org/10.1101/2022.07.31.22278064
Subject Area
Subject Areas
- Addiction Medicine (215)
- Allergy and Immunology (495)
- Anesthesia (106)
- Cardiovascular Medicine (1095)
- Dermatology (141)
- Emergency Medicine (274)
- Epidemiology (9765)
- Gastroenterology (480)
- Genetic and Genomic Medicine (2308)
- Geriatric Medicine (222)
- Health Economics (462)
- Health Informatics (1557)
- Health Policy (734)
- Hematology (236)
- HIV/AIDS (503)
- Medical Education (237)
- Medical Ethics (67)
- Nephrology (257)
- Neurology (2141)
- Nursing (134)
- Nutrition (336)
- Oncology (1175)
- Ophthalmology (364)
- Orthopedics (128)
- Otolaryngology (220)
- Pain Medicine (146)
- Palliative Medicine (50)
- Pathology (311)
- Pediatrics (695)
- Primary Care Research (267)
- Public and Global Health (4654)
- Radiology and Imaging (776)
- Respiratory Medicine (623)
- Rheumatology (274)
- Sports Medicine (210)
- Surgery (251)
- Toxicology (43)
- Transplantation (120)
- Urology (94)